MLchartDataset catalogue

anti-PD-1/anti-VEGF bispecific antibody MHB039A

Term · Oncology and biomedicine · MLC-T-ONC-010985

A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-1/anti-VEGF bispecific antibody MHB039A simultaneously targets and binds to both PD-1 expressed on T cells and VEGF expressed on tumor cells. The binding of MHB039A to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of MHB039A to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.

Table 1. Record
IdentifierMLC-T-ONC-010985
FieldOncology and biomedicine
Synonymsanti-PD-1/VEGF bispecific antibody MHB039A; anti-VEGF/anti-PD-1 bispecific antibody MHB039A; PD-1 x VEGF bispecific antibody MHB039A
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010985",
  "term": "anti-PD-1/anti-VEGF bispecific antibody MHB039A",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-1/anti-VEGF bispecific antibody MHB039A simultaneously targets and binds to both PD-1 expressed on T cells and VEGF expressed on tumor cells. The binding of MHB039A to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274) and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of MHB039A to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.",
  "synonyms": [
    "anti-PD-1/VEGF bispecific antibody MHB039A",
    "anti-VEGF/anti-PD-1 bispecific antibody MHB039A",
    "PD-1 x VEGF bispecific antibody MHB039A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-1-anti-vegf-bispecific-antibody-mhb039a/"
}

Record 2,115 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.